Connect with us

Pregnancy

Distance affects use of telehealth to access abortion pills

Published

on

The distance between a patient’s home and an abortion-services facility where they would seek care significantly influences how they receive birth-control medications, according to a new study.

The research began at the start of the Covid-19 pandemic, when receiving abortion medication via telehealth and through the mail was novel, before the U.S. Supreme Court’s Dobbs decision, which overturned the constitutional right to an abortion.

“Basically, the farther the patients resided from an abortion facility, the more they were depending on the pills being mailed to them,” said co-lead author Dr. Emily Godfrey, a UW Medicine OB-GYN and family medicine physician.

Over the study span and beyond, “there was exponential growth” of patients opting to receive their pills via telehealth and the mail, Godfrey said.

The investigators acquired electronic medical record data from Aid Access users in 21 states and Washington, D.C. Aid Access is a nonprofit that works with clinicians across the country who provide patients with FDA-approved abortion pills. Western states included in the study were Washington, Idaho, Oregon, California, Alaska and Nevada.

The researchers tallied telehealth requests for medication abortion from 8,411 individuals.

“With abortion now banned or highly restricted in 22 U.S. states, telehealth abortion services are necessary to maintain essential reproductive health services,” the authors concluded.

The authors used the Centers for Disease Control and Prevention’s (CDC) county-level Social Vulnerability Index to better understand the socioeconomic status of those who requested Aid Access services.

They found that people living in lower socioeconomic counties had a higher likelihood of seeking medication abortion via telehealth compared to persons living in higher socioeconomic counties.

Researchers found that, for every 100 miles of distance from an abortion facility, the per capita probability increased by 61 per cent that a patient would access abortion medication via telehealth. Patients accessing telehealth to obtain medication abortions now constitute 20 per cent of all U.S. abortions, the authors noted.

In total, medication abortions comprise 63 per cent of all abortions in the United States, according to the Guttmacher Institute.

Most individuals who obtained a medication abortion via telehealth were 20-29 years old, did not have children, and were at less than 6 weeks gestation. More than half of the total fulfilled requests went to individuals in four states: California (21 per cent), New York (17 per cent), Nevada (10 per cent), and New Jersey (10 per cent).

“This study gives us an idea of the sheer volume of patients using these services,” said Anna Fiastro, a UW Medicine researcher in family medicine and co-lead author of the paper.

The study confirms that the demand for abortion pills mifepristone and misoprostol has increased over time as more patients turn to telehealth and the mail in response to tighter state restrictions, Fiastro said.

“I think it is remarkable that many using the mail and telehealth option were under six weeks of pregnancy duration,” Fiastro said. This finding, she added, reflects that this type of access is quick, cost-effective and safe. More of the telehealth users (51%) said they chose this option because of its low cost, compared with an in-clinic visit.

During the two-year study period, telehealth medication abortion requests that did not require in-clinic testing jumped by 15 times, to more than 1,000 requests a month, the authors noted. This represented one-third of all virtual abortions before the Dobbs decision.

As of March 2024, beyond the study period, licensed U.S. physicians are fulfilling close to 10,000 requests per month in states with abortion restrictions or bans, the paper stated.

Maintaining access to abortion medication is a “critically necessary healthcare service,” the authors asserted. “Especially for individuals who are young, socially vulnerable and live in counties far from abortion facilities.”

Fertility

Paracetamol use may impact future fertility, studies suggest

Published

on

Paracetamol use in pregnancy was not linked to autism or ADHD, while separate research found reproductive differences in girls exposed before birth.

One study analysed health records from more than 120,000 children and found no increased risk of autism following prenatal paracetamol exposure.

A separate analysis of nearly 100,000 children also found no increased risk of ADHD among those born to mothers who used the painkiller during pregnancy.

Researchers from the Hong Kong Hospital Authority examined electronic health records covering pregnancies between January 2001 and December 2023.

The autism analysis included 124,333 children, who were nine years old on average and split almost evenly between males and females. There were 3,445 autism diagnoses, representing 2.8 per cent of the group.

The ADHD analysis involved 97,285 children, who were seven years old on average and also split evenly between males and females. There were 5,168 ADHD diagnoses, representing 5.3 per cent.

Women prescribed paracetamol during pregnancy were more likely to be older and have pre-existing conditions including psychiatric disorders, as well as reasons for taking the drug such as infection, fever or chronic pain.

No association was found between prenatal paracetamol exposure and either autism or ADHD.

The findings did not differ according to the trimester in which paracetamol was taken or whether use was intermittent or daily. Advanced maternal age, defined as pregnancy in women over 35, did not alter the findings.

The researchers wrote: “Paracetamol remains a safe and essential analgesic [pain reliever] and antipyretic [fever reducer] during pregnancy, whereas alternatives, such as NSAIDs and opioids carry well-documented risks.

“Unwarranted reluctance to use paracetamol could lead to undertreatment of pain and fever, or the use of more harmful alternatives, both posing risks to the pregnancy and developing fetus.”

The authors said women should assess paracetamol use with guidance from their doctor.

A separate study involving 685 pregnant women without pre-existing conditions and 302 infant daughters found associations between prenatal paracetamol exposure and differences in reproductive organs and hormone levels.

Researchers from Copenhagen University Hospital enrolled the women during their first trimester and assessed them during the first trimester, third trimester and again when their babies were three months old.

At around three months, infants experience a temporary rise in reproductive hormones sometimes called mini-puberty.

Pregnant participants completed questionnaires every two weeks about their use of pain medicines including paracetamol. Infant girls underwent ultrasound scans of their reproductive organs and blood tests to measure hormone levels.

Researchers also examined a separate group of 1,210 girls followed from infancy to adolescence whose mothers reported paracetamol use during the third trimester.

Three-month-old girls exposed to paracetamol before birth had an average 40 per cent smaller ovarian volume, 13 per cent smaller uterine volume and 23 per cent fewer ovarian follicles.

Girls exposed during the first trimester also had lower levels of Anti-Müllerian hormone, a marker of ovarian function.

Among the older girls, those exposed before birth were more likely to have smaller uteruses at puberty and smaller ovaries during their teenage years.

Dr Margit Bistrup Fischer, lead study author and postdoctoral researcher in the Department of Growth and Reproduction at Rigshospitalet hospital in Denmark, said: “Animal studies have demonstrated that impaired formation of ovarian follicles can lead to reduced fertility and earlier reproductive aging.

“Whether the differences observed in our study have implications for fertility and age at menopause in humans remains unknown and will require long-term follow-up of the girls in our cohort.”

She cautioned that women who had used paracetamol during pregnancy “should not be alarmed by our findings”, as the study found associations rather than direct causation and outcomes for individual women and children are unclear.

“Importantly, our study does not evaluate whether [acetaminophen] causes reproductive problems, nor does it provide evidence that prenatal exposure affects future fertility or age at menopause,” she said.

“Although we observed similar associations in an independent cohort, long-term follow-up is needed to determine whether these early-life differences have any clinical significance later in life.”

Continue Reading

Pregnancy

Pregnant women prioritised as NHS rolls out flu vaccine

Published

on

Pregnant women are among the first groups offered the NHS flu vaccine this winter, which has been updated to better match the subclade K strain.

Schoolchildren are also being prioritised and, like pregnant women, can receive the vaccine from September because they can catch and spread flu easily.

Protecting them also helps others, including younger siblings and grandparents.

Other eligible groups, including people aged 65 and over, will be able to receive a free NHS flu vaccine from October and should receive an invitation by phone or post.

Dr Amanda Doyle from NHS England said: “Last year’s flu season came early and was made worse by a new variant, which had a major impact for patients and put enormous pressure on urgent and emergency care services across the country.

“With the NHS experiencing its busiest summer on record, staff have started preparing for this winter earlier than ever – and with services already under significant pressure, it is vital that everyone offered the vaccine comes forward.”

Last winter’s flu season began more than a month earlier than usual as a new mutated strain circulated.

The strain was sometimes referred to as “Super flu”, although this is not a medical term and does not mean the virus is harder to treat. The name reflected that people had yet to build up immunity against it.

Flu vaccines are updated each year to better match the influenza viruses expected to circulate. These viruses continually mutate, so experts must predict how they are likely to change.

This winter’s vaccine includes changes intended to provide a better match for subclade K.

It remains unclear when flu will begin circulating widely this winter or how severe the season will be. Experts often look at flu activity in southern hemisphere countries such as Australia and New Zealand for indications of how the UK season could develop.

Their flu season peaks in July or August. Australia has recorded fewer cases than last year, while New Zealand has experienced high numbers.

Everyone is at risk of catching flu, regardless of age or how fit and healthy they are.

Doyle said: “Flu can really knock you for six, and for some children and pregnant women it can mean becoming seriously ill or ending up in hospital.”

The flu vaccine cannot give you flu. Instead, it helps the body know how to fight the virus.

Children aged two and over receive a nasal spray version, while adults receive an injection. One dose is needed ahead of winter.

Free NHS flu vaccines are available through pharmacies, GPs and schools. People who are not eligible for a free vaccination can pay around £10 to £20.

Schoolchildren and pregnant women can receive a free NHS flu vaccine from September onwards.

From October, free vaccination will also be available to children aged two or older who have not yet started school, people aged 65 and over, those with certain long-term health conditions, care home residents and carers of older or disabled people, including those receiving a carer’s allowance.

It will also be available to people living with someone who has a weakened immune system and those experiencing homelessness or staying in a homeless hostel or night shelter.

More adults will also be offered vaccination against respiratory syncytial virus (RSV), a virus that attacks the lungs, this winter.

From September, adults with certain pre-existing health conditions, such as chronic lung disease, will be invited for the RSV vaccine when they turn 65 rather than waiting until 75.

Continue Reading

Pregnancy

New universal heart attack definition could transform care for women

Published

on

Four leading cardiovascular health groups have agreed new guidance for healthcare professionals assessing patients with suspected heart attacks.

Historically, some less common forms of heart attack, which evidence shows affect women far more than men, have been classified as less important, with treatment and care often worse as a result.

Experts said women had been receiving less effective treatments that did not always target the specific cause of their heart attack and could even make them more unwell.

The changes were announced in Munich on the opening day of the annual congress of the European Society of Cardiology (ESC).

Professor Bryan Williams, chief scientific and medical officer of the British Heart Foundation, said: “This is a landmark moment, a radical shift in how we define and diagnose heart attacks worldwide which will transform people’s care.

“For decades, women have missed out on accurate diagnoses and treatment.

“This focus on finding less common causes of heart attacks, which predominantly affect women, should help to change that. It could be life-changing for huge numbers of women in the UK and worldwide.”

The new guidance upgrades three types of heart attack that can be up to 10 times more common in women and are often caused by childbirth, exercise and emotional stress.

The most serious cases, previously known as “type 1” and now classed as “primary” heart attacks, had previously prioritised those caused by a clot blocking blood flow to the heart.

Other forms can involve reduced blood flow for different reasons, including the tightening or tearing of coronary arteries. These can be more likely to be missed or treated less urgently.

The guidance also introduces a lower diagnostic threshold for women based on levels of troponin, a protein released into the blood when the heart is injured and damaged.

Previously, women were expected to meet the same troponin threshold as men to receive a diagnosis.

Williams said the streamlined heart attack categories would also help patients understand the cause of their heart attack and what comes next.

The three upgraded types are coronary artery spasm, coronary embolism and spontaneous coronary artery dissection (SCAD).

Coronary artery spasm involves the tightening of an artery, which can deprive the heart muscle of blood and oxygen. It can be caused by emotional stress, exercise or extreme cold.

Coronary embolism occurs when a blood clot or fatty deposit travels to a coronary artery and causes a blockage.

SCAD is caused by a tear in a coronary artery. Around 80 per cent of cases occur in women, and it often happens during or soon after pregnancy.

Professor Nicholas Mills, a cardiologist at the University of Edinburgh who led the international taskforce behind the guidance, said it was “the first time that we’ve had a truly global approach to aligning how we diagnose what is probably the most important diagnosis there is”.

He said: “It kills so many people, and we’ve never got everyone together around the world to agree how we’re going to describe it, classify it, explain it to our patients.

“Our job now is to implement this as widely as possible. It’s just as relevant for the UK as it is for any other country around the world. It is a revolution. It’s going to make care better for patients.”

Mills said there had been “unintended systematic bias against women”, including through the use of the key blood test for diagnosing heart attacks at an average level, which picks up all men but misses some women.

He said: “This is used for all types of heart attack in every emergency department in the world, and we want to make sure that it’s used correctly.”

The guidance was drawn up by the ESC, the American College of Cardiology, the American Heart Association and the World Heart Federation.

Continue Reading

Trending

Copyright © 2025 Aspect Health Media Ltd. All Rights Reserved.